Pfizer Inc. Files 8-K on Shareholder Vote Matters

Ticker: PFE · Form: 8-K · Filed: 2024-04-29T00:00:00.000Z

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

Related Tickers: PFE

TL;DR

Pfizer's voting on something important, details to come.

AI Summary

On April 25, 2024, Pfizer Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not contain specific details about the vote itself, the proposals, or the outcome, but indicates that a shareholder vote is scheduled or has occurred.

Why It Matters

This filing signals that Pfizer is engaging in a formal process of seeking shareholder approval or input on significant corporate decisions, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any immediate financial or operational risks.

Key Players & Entities

FAQ

What specific matters are being submitted for a vote of Pfizer's security holders?

The filing does not specify the exact matters being submitted for a vote; it only states that such matters are being presented.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on April 25, 2024.

What is Pfizer Inc.'s principal executive office address?

Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York, 10001-2192.

What is Pfizer Inc.'s I.R.S. Employer Identification Number?

Pfizer Inc.'s I.R.S. Employer Identification Number is 13-5315170.

Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

From the Filing

0000078003-24-000101.txt : 20240429 0000078003-24-000101.hdr.sgml : 20240429 20240429101915 ACCESSION NUMBER: 0000078003-24-000101 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240425 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240429 DATE AS OF CHANGE: 20240429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 24887645 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 pfe-20240425.htm PFIZER 8-K APRIL 25 2024 pfe-20240425 0000078003 false 0000078003 2024-04-25 2024-04-25 0000078003 us-gaap:CommonStockMember 2024-04-25 2024-04-25 0000078003 pfe:NotesDue20271.000Member 2024-04-25 2024-04-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.  20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2024 PFIZER INC . (Exact name of registrant as specified in its charter) Delaware 1-3619 13-5315170 (State or other (Commission File (I.R.S. Employer jurisdiction of Number) Identification No.) incorporation)     66 Hudson Boulevard East 10001-2192 New York, New York (Zip Code) (Address of principal executive offices) Registrant’s telephone number, including area code: ( 212 ) 733-2323 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $.05 par value PFE New York Stock Exchange 1.000% Notes due 2027 PFE27 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company     ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐ Item 5.07 Submission of Matters to a Vote of Security Holders (a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 25, 2024. (b) Shareholders voted on the matters set forth below. 1. The nominees for election to the Company’s Board of Directors set forth in Item 1 to the Company’s Proxy Statement filed with the U.S. Securities and Exchange Commission on March 14, 2024 were elected to hold office until the Company’s next Annual Meeting of Shareholders, based upon the following votes: Nominee Votes For       Vot

View on Read The Filing